Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110

The First BiTE Antibody for Treatment of Solid Tumors

28-Apr-2008

Micromet, Inc. announced the start of a phase 1 clinical trial with its BiTE® antibody MT110. The study will explore the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of MT110 in patients with lung and gastrointestinal cancers.

MT110 targets the epithelial cell adhesion molecule (EpCAM or CD326), which is highly expressed on colon, lung, breast, prostate, ovarian, gastric and pancreas cancers. Additionally, EpCAM has been found on cancer stem cells of colon, breast, prostate and pancreas cancers. Cancer stem cells are believed to cause metastases and recurrence of these cancers. MT110 is the second BiTE antibody in clinical trials, and the fourth clinical program in Micromet's product pipeline. The first BiTE antibody, MT103 (MEDI-538), is now in phase 1 and phase 2 clinical trials for the treatment of haematological cancers.

"BiTE antibodies enable the patients' own T cells to very efficiently eliminate tumor cells," comments Patrick Baeuerle, Chief Scientific Officer of Micromet, "In various experimental tumor models, we have demonstrated the high therapeutic potential of EpCAM-specific BiTE antibodies, and we are now looking forward to determining the safety and the therapeutic potential of MT110 in patients."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous